A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
| Autor: | Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators, Salloway, S |
|---|---|
| Zdroj: | Neurology; 12/15/2009, Vol. 73 Issue 24, p2061-2070, 10p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|